Does ACHV pay a dividend and is it safe?

Achieve Life Sciences Inc. (ACHV) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / ACHV / dividends

MYGN (47) QDEL (21) NNNN (35) TKNO (42) ⌘ Pro Terminal →

Achieve Life Sciences Inc. (ACHV) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.61 -3.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.56

Achieve Life Sciences Inc. (ACHV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $702.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACHV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACHV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Achieve Life Sciences Inc. (NASDAQ: ACHV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.61 (-3.22% 1D, market cap $702.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ACHV ranks #484 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACHV compare to MYGN and QDEL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ACHV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M) and QDEL (QuidelOrtho Corporation) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $908.6M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACHV?

▼

Per ACHV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000949858), Achieve Life Sciences Inc. generated $17.6M in revenue (+8.2% YoY), -$54.6M in net income, and -$49.5M in free cash flow against $41.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.56 (-0.77%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACHV)Realized 20D OHLCV Swing Band: ±11.8%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ACHV SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.00-7% Next Q

Q2 (-2Q)

Grade D$6.51+6.5% Next Q

Q3 (-1Q)

Grade D$6.93-4.6% Next Q

Current

Grade D-$6.61-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACHV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACHV currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.41) and Max Pain ($6.94) forces dealer call-delta covering toward $9.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACHV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACHV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHV)

✓Walkthrough of ACHV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACHV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.57%🛡️ HOLDING TREND SUPPORT

2026-11-03O $7.19H $7.19L $6.61C $6.61VOL 1.38M

RES: $10.53SUP: $6.31SMA50: $7.41SMA200: $5.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACHV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACHV Butterfly Map → + Track ACHV →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACHV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACHV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACHV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHV)

Health Care Rank #484 of 1015 ⚔️ MYGN vs ACHV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACHV vs. MYGN, QDEL, NNNN, TKNO)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Achieve Life Sciences Inc. (ACHV) ranks #484 by composite RQD confidence (39/100, grade D-) and #394 by equity capitalization ($702.8M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACHV at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACHV ACTIVE Achieve Life Sciences Inc.	D-	39/100	—	—	-35.0%	-3.22%	$702.8M	Benchmark Subject
MYGN Myriad Genetics Inc.	D	47/100	—	69.9%	-35.0%	-7.87%	$607.4M	/mygn-vs-achv →
QDEL QuidelOrtho Corporation	E	21/100	—	—	-35.0%	+5.89%	$908.6M	/qdel-vs-achv →
NNNN Anbio Biotechnology (Class A)	D-	35/100	83.6x	87.2%	17.0%	+4.46%	$483.5M	/nnnn-vs-achv →
TKNO Alpha Teknova Inc.	D-	42/100	—	33.2%	-21.3%	-4.75%	$454.1M	/tkno-vs-achv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000949858 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported GAAP revenue of $17.6M (+8.2% vs. FY2024 revenue of $16.2M , and -86.9% cumulative change since FY2023) , GAAP net income of -$54.6M, operating cash flow of -$49.5M, and free cash flow of -$49.5M (-66.2% YoY). On the balance sheet, ACHV closed FY2025 with $41.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$17.6M	-$54.6M	-$49.5M	-$49.5M	$41.8M	—
FY2024 (FY)	2024-12-31	$16.2M	-$39.8M	-$29.8M	-$29.8M	$38.6M	—
FY2023 (FY)	2023-12-31	$134.2M	-$29.8M	-$24.5M	-$24.5M	—	—

3. ACHV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACHV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACHV compare to MYGN and QDEL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACHV?

Where is ACHV trading relative to its 50-day, 200-day, and 52-week technical levels?

ACHV last traded at $6.61 (-3.22% on volume of 1,531,856 shares), positioning the stock -10.80% below its 50-day simple moving average ($7.41) and +16.99% above its 200-day simple moving average ($5.65). Across its 52-week range of $2.62 to $8.64, ACHV sits at the 66.3% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($5.83 to $7.39).

Direct Sub-Reports: ACHV RQD Cockpit ACHV 12M Forecast ACHV Earnings & Move ACHV Dividends & DRIP ACHV Insiders & 13F ACHV Whale Options ACHV Profit Sankey ACHV News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ACHV — Achieve Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Achieve Life Sciences Inc. (ACHV) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.61 (-3.22% 1D, market capitalization $702.8M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.69%.
Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Achieve Life Sciences Inc. (ACHV) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported $17.6M in annual revenue (up from $16.2M in FY2024, +8.2% YoY) and -$54.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($134.2M revenue, -$29.8M net income) through FY2025, ACHV scaled operating cash flow to -$49.5M and free cash flow to -$49.5M, backed by $41.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.69% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $2.62 – $8.64 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ACHV carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can ACHV sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $17.6M and free cash flow of -$49.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ACHV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACHV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Achieve Life Sciences Inc. (ACHV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACHV Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 1d ago

Achieve Life Sciences Stock Price Forecast. Should You Buy ACHV?

StockInvest.us report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Yahoo Finance report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Achieve Life Sciences (NASDAQ:ACHV) Stock Jumps 3.2% - Here's Why

MarketBeat report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Achieve Life Sciences, Inc. Estimates – NASDAQ:ACHV

TradingView report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Achieve Life Sciences (ACHV) Stock Price, Chart & Analysis

www.debelegger.nl report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Achieve Life Sciences (NasdaqCM:ACHV) Stock Forecast & Analyst Predictions

Simply Wall St report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

After an inactive-treatment trial, 39.4% of those still smoking or vaping had quit by the final month.

Stock Titan report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 2d ago

H.C. Wainwright reiterates Achieve Life Sciences stock rating on trial data

Investing.com report covering Achieve Life Sciences Inc. (ACHV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACHV Bull vs. Bear Conversation Board — What's Your Call at $6.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACHV 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $8.40 (+23.0%)

📌 Pinned Debate

Whale/13F flow scores 11 of 20 and the stock rose 4.96% to $7.19, near the upper end of its $2.62–$8.64 52-week range.

The street is overcomplicating Achieve Life Sciences Inc. (ACHV). Whale/13F flow scores 11 of 20 and the stock rose 4.96% to $7.19, near the upper end of its $2.62–$8.64 52-week range.. With an RQD score of 39/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $7.38.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 10/20 institutional whale-flow stock at $6.83 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $5.40 (-20.9%)

Spot @ $6.83

ROIC of -35%, FCF of -$49.5M, and a Piotroski F-Score of 2/9 indicate a weak cash engine and balance-sheet profile.

ROIC of -35%, FCF of -$49.5M, and a Piotroski F-Score of 2/9 indicate a weak cash engine and balance-sheet profile.. Look at the math on ACHV: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $6.01 before getting long.